SECTION 1: IDENTIFICATION

1.1. Product Identifier
Product Form: Mixture
Product Name: Tarceva® (erlotinib) Tablets
Material Name: Erlotinib hydrochloride
Chemical Formula of Active Ingredient: C_{22}H_{23}N_{3}O_{4}·HCl
Chemical Name of Active Ingredient: N-((3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine

1.2. Intended Use of the Product
Use of the substance/mixture: Non-small cell lung cancer. For professional use only.

1.3. Name, Address, and Telephone of the Responsible Party
Company
Astellas US LLC
1 Astellas Way
Northbrook, IL 60062
Tel.: 800-888-7704
www.us.astellas.com

1.4. Emergency Telephone Number
Emergency Number: 800-727-7003 Medical Communications

SECTION 2: HAZARDS IDENTIFICATION

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii).

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii).

SECTION 4: FIRST AID MEASURES

4.1. Description of First Aid Measures
First-aid Measures General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label if possible).
First-aid Measures After Inhalation: Remove to fresh air and keep at rest in a position comfortable for breathing. Obtain medical attention if breathing difficulty persists.
First-aid Measures After Skin Contact: Remove contaminated clothing. Gently wash with plenty of soap and water followed by rinsing with water for at least 15 minutes. Call a POISON CENTER or doctor/physician if you feel unwell. Wash contaminated clothing before reuse.
First-aid Measures After Eye Contact: Rinse cautiously with water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention.
First-aid Measures After Ingestion: Do not induce vomiting. Rinse mouth. Immediately call a POISON CENTER or doctor/physician.

4.2. Most important symptoms and effects, both acute and delayed
Symptoms/Injuries: Pharmaceutical. When handling in workplace settings, in quantities that are most likely above the therapeutic dose, this product may be harmful if absorbed through the eyes, skin, or respiratory tract.
Symptoms/Injuries After Inhalation: If tablet is crushed: May cause respiratory irritation.
Symptoms/Injuries After Skin Contact: May cause an allergic skin reaction.
Symptoms/Injuries After Eye Contact: If tablet is crushed: Causes eye irritation.
Symptoms/Injuries After Ingestion: May be harmful if swallowed.
Chronic Symptoms: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed
If you feel unwell, seek medical advice (show the label where possible).

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media
Suitable Extinguishing Media: Water spray, fog, alcohol-resistant foam, dry chemical, carbon dioxide.
Unsuitable Extinguishing Media: Do not use a heavy water stream. Use of heavy stream of water may spread fire.
5.2. Special Hazards Arising From the Substance or Mixture
Fire Hazard: Not considered flammable but may burn at high temperatures.
Explosion Hazard: Product is not explosive.
Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters
Precautionary Measures Fire: Exercise caution when fighting any chemical fire.
Firefighting Instructions: Use water spray or fog for cooling exposed containers.
Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.
Other Information: Refer to Section 9 for flammability properties.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures
General Measures: Use only as directed.
6.1.1. For Non-emergency Personnel
Protective Equipment: Use appropriate personal protection equipment (PPE).
6.1.2. For Emergency Responders
Protective Equipment: Equip cleanup crew with proper protection.
Emergency Procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

6.2. Environmental Precautions
Prevent entry to sewers and public waters. Notify authorities if product enters sewers or public waters.

6.3. Methods and Material for Containment and Cleaning Up
For Containment: Contain and collect as any solid.
Methods for Cleaning Up: Clean up spills immediately and dispose of waste safely. Sweep spilled substance into containers; if appropriate, moisten first to prevent dusting. Contact competent authorities after a spill.

6.4. Reference to Other Sections
See Heading 8. Exposure controls and personal protection. For further information refer to section 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling
Additional Hazards When Processed: Avoid breaking or crushing tablets.
Hygiene Measures: Handle in accordance with good industrial hygiene and safety procedures. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work.

7.2. Conditions for Safe Storage, Including Any Incompatibilities
Technical Measures: Comply with applicable regulations.
Storage Conditions: Store in a dry, cool and well-ventilated place. Keep container closed when not in use. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.
Incompatible Products: Strong acids, strong bases, strong oxidizers.
Storage Temperature: 25 °C (77 °F); excursions permitted to 15 °C - 30 °C (59 °F - 86 °F)

7.3. Specific End Use(s)
Non-small cell lung cancer. For professional use only.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control Parameters
For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), NIOSH (REL), or OSHA (PEL).

8.2. Exposure Controls
Appropriate Engineering Controls: Ensure adequate ventilation, especially in confined areas. Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure all national/local regulations are observed.
Personal Protective Equipment: Gloves.

Materials for Protective Clothing: Chemically resistant materials and fabrics.
Hand Protection: Wear chemically resistant protective gloves.
Eye Protection: Chemical goggles or safety glasses.
Skin and Body Protection: Wear suitable protective clothing.
Respiratory Protection: None required under normal product handling conditions. Use NIOSH-approved dust mask if dust has the potential to become airborne.
Environmental Exposure Controls: Do not allow the product to be released into the environment.
Consumer Exposure Controls: Do not eat, drink or smoke during use.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties

<table>
<thead>
<tr>
<th>Physical State</th>
<th>Solid</th>
</tr>
</thead>
</table>

Appearance:
25 mg tablets: White film-coated tablets for daily oral administration. Round, biconvex face and straight sides, white film-coated, printed in orange with a “T” and “25” on one side and plain on the other side.
100 mg tablets: White film-coated tablets for daily oral administration. Round, biconvex face and straight sides, white film-coated, printed in gray with “T” and “100” on one side and plain on the other side.
150 mg tablets: White film-coated tablets for daily oral administration. Round, biconvex face and straight sides, white film-coated, printed in maroon with “T” and “150” on one side and plain on the other side.

Odor: No data available
Odor Threshold: No data available
pH: Aqueous solubility of erlotinib hydrochloride is dependent on pH with increased solubility at a pH of less than 5 due to protonation of the secondary amine. Over the pH range of 1.4 to 9.6, maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2.

Evaporation Rate: No data available
Melting Point: No data available
Freezing Point: No data available
Boiling Point: No data available
Flash Point: No data available
Auto-ignition Temperature: No data available
Decomposition Temperature: No data available
Flammability (solid, gas): No data available
Vapor Pressure: No data available
Relative Vapor Density at 20 °C: No data available
Relative Density: No data available
Solubility: Very slightly soluble in water, slightly soluble in methanol and practically insoluble in acetonitrile, acetone, ethyl acetate and hexane.

Partition Coefficient: N-Octanol/Water: No data available
Viscosity: No data available
Molecular Weight Of Active Ingredient: 429.90 g/mol

9.2. Other Information: No additional information available.

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity: Hazardous reactions will not occur under normal conditions.
10.2. Chemical Stability: Stable under recommended handling and storage conditions (see section 7).
10.3. Possibility of Hazardous Reactions: Hazardous polymerization will not occur.
10.5. Incompatible Materials: Strong acids, strong bases, strong oxidizers.
### SECTION 11: TOXICOLOGICAL INFORMATION

#### 11.1. Information On Toxicological Effects

**Acute Toxicity:** Not classified

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum Lethal Dose Oral Rat</td>
<td>1000 mg/kg</td>
</tr>
<tr>
<td>Minimum Lethal Dose Oral Mouse</td>
<td>2000 mg/kg</td>
</tr>
<tr>
<td>Minimum Lethal Dose Oral Dog</td>
<td>&gt; 200 mg/kg</td>
</tr>
<tr>
<td>Minimum Lethal Dose Intravenous Rat</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Minimum Lethal Dose Intravenous Mouse</td>
<td>75 mg/kg</td>
</tr>
<tr>
<td>Minimum Lethal Dose Intravenous Dog</td>
<td>&gt; 15 mg/kg</td>
</tr>
</tbody>
</table>

**Additional information**

Acute effects included a transient decrease in activity and irregular respiration (2000 mg/kg, oral) and a decrease in body weight gain (500, 1000, 2000 mg/kg, oral) in mice and rats. Acute effects in dogs included emesis, decreased activity, pale gums, cold skin, tremors, salivation, and/or ataxia (200 mg/kg, oral). Intravenous administration produced convulsions at 25 mg/kg or greater in mice, or 35 mg/kg or greater in rats. Intravenous administration to dogs caused transient ataxia, pale gums, pupil dilation, tremors, elevated heart rate, and depressed blood pressure.

<table>
<thead>
<tr>
<th>Magnesium stearate (557-04-0)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LD50 Oral Rat</td>
<td>&gt; 2000 mg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glycolic acid, sodium salt (2836-32-0)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LD50 Oral Rat</td>
<td>7110 mg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sodium lauryl sulfate (151-21-3)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LD50 Oral Rat</td>
<td>1288 mg/kg</td>
</tr>
<tr>
<td>LD50 Dermal Rabbit</td>
<td>580 mg/kg</td>
</tr>
<tr>
<td>LC50 Inhalation Rat</td>
<td>&gt; 3900 mg/m³ (Exposure time: 1 h)</td>
</tr>
</tbody>
</table>

**Skin Corrosion/Irritation:** Not classified

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>Minimal skin irritation was seen in rabbits.</td>
</tr>
</tbody>
</table>

**Serious Eye Damage/Irritation:** Not classified

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>When the eyes of rabbits were treated with erlotinib, there was a clear discharge, slight conjunctival reddening and chemosis.</td>
</tr>
</tbody>
</table>

**Respiratory or Skin Sensitization:** May cause an allergic skin reaction.

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>In the guinea pig maximization test, erlotinib was considered a mild skin sensitizer.</td>
</tr>
</tbody>
</table>

**Germ Cell Mutagenicity:** Not classified

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>Erlotinib did not have genotoxicity in a series of in vitro assays (bacterial mutation, human lymphocyte chromosome aberration, and mammalian cell mutation) and an in vivo mouse bone marrow micronucleus test.</td>
</tr>
</tbody>
</table>

**Carcinogenicity:** Not classified

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>Erlotinib was negative for carcinogenicity following 2 years of oral administration to rats and mice.</td>
</tr>
</tbody>
</table>

**Reproductive Toxicity:** Suspected of damaging the unborn child.

<table>
<thead>
<tr>
<th>Erlotinib (183321-74-6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional information</td>
<td>No teratogenic effects were observed in rabbits or rats. Erlotinib has been shown to cause embryo/fetal lethality associated with maternal toxicity and abortion in rabbits when given at doses that result in plasma drug concentrations of approximately 3 times those in humans (AUCs at 150 mg daily dose). When given to achieve plasma drug concentrations approximately equal to those in humans, there was no</td>
</tr>
</tbody>
</table>
Tarceva® (erlotinib) Tablets
Safety Data Sheet
According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

Increased incidence of embryo/fetal lethality or abortion in rabbits or rats. However, female rats treated with 30 mg/m²/day or 60 mg/m²/day (0.3 or 0.7 times the clinical dose, on a mg/m² basis) of erlotinib prior to mating through the first week of pregnancy had an increase in early resorptions which resulted in a decrease in the number of live fetuses. Erlotinib did not impair fertility in either male or female rats at doses up to 60 mg/m²/day.

Specific Target Organ Toxicity (Single Exposure): Not classified
Specific Target Organ Toxicity (Repeated Exposure): May cause damage to organs through prolonged or repeated exposure.

Erlotinib (183321-74-6)

Additional information
Repeat oral toxicity studies up to 6 months and 12 months have been conducted in rats and dogs, respectively. Effects in rats treated with 30 mg/m²/day or 60 mg/m²/day (0.3 or 0.7 times the clinical dose, on a mg/m² basis) of erlotinib included decreased food consumption and body weight gain, increases in total bilirubin, and marginal increases in alanine aminotransferase (ALT), ovarian atrophy, renal papillary necrosis with tubulardilatation, multifocal necrosis, angiectasis of the adrenal gland, and follicular degeneration/inflammation of the skin. In dogs, a decrease in body weight at 150 mg/m²/day or greater, reddening of the skin, and buccal mucus membrane at 50 mg/m²/day or greater were seen.

Aspiration Hazard: Not classified
Symptoms/Injuries After Inhalation: If tablet is crushed: May cause respiratory irritation.
Symptoms/Injuries After Skin Contact: May cause an allergic skin reaction.
Symptoms/Injuries After Eye Contact: If tablet is crushed: Causes eye irritation.
Symptoms/Injuries After Ingestion: May be harmful if swallowed.
Chronic Symptoms: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Sodium lauryl sulfate (151-21-3)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LC50 Fish 1</td>
<td>8 (8 - 12.5) mg/l (Exposure time: 96 h - Species: Pimephales promelas [static])</td>
</tr>
<tr>
<td>EC50 Daphnia 1</td>
<td>1.8 mg/l (Exposure time: 48 h - Species: Daphnia magna)</td>
</tr>
<tr>
<td>LC 50 Fish 2</td>
<td>15 (15 - 18.9) mg/l (Exposure time: 96 h - Species: Pimephales promelas [static])</td>
</tr>
</tbody>
</table>

12.2. Persistence and Degradability
No additional information available.

12.3. Bioaccumulative Potential

Sodium lauryl sulfate (151-21-3)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCF fish 1</td>
<td>(will not bioconcentrate)</td>
</tr>
<tr>
<td>Log Pow</td>
<td>1.6</td>
</tr>
</tbody>
</table>

12.4. Mobility in Soil
No additional information available.

12.5. Other Adverse Effects
No additional information available.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods
Waste Disposal Recommendations: Dispose of contents and container according to local, regional, national, and international regulations.


SECTION 14: TRANSPORT INFORMATION

14.1. In Accordance with DOT
Not regulated for transport.

14.2. In Accordance with IMDG
Not regulated for transport.

14.3. In Accordance with IATA
Not regulated for transport.

SECTION 15: REGULATORY INFORMATION

15.1 US Federal Regulations
Not applicable

15.2 US State Regulations
Not applicable
SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>06/10/2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Information</td>
<td>This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200. This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.</td>
</tr>
</tbody>
</table>

Astellas US GHS SDS